Sugi Predict

Sugi Predict / Compounds / SCHEMBL13650607

SCHEMBL13650607

SCHEMBL13650607

Cc1cnn2c(O)cc(O)nc12

nearest known ligand 0.34

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.34
▸ HTT P42858 1/20 0.33
▸ CSNK2A1 P68400 2/20 0.33
▸ MAPT P10636 2/20 0.32
▸ PDE4B Q07343 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21754311 0.81 KDM4E (0.42) KDM4EHTTCSNK2A1MAPTPDE4B
SCHEMBL23152044 0.77 CDK2 (0.38) KDM4ECSNK2A1PDE4BALDH1A1HPGD
SCHEMBL1367838 0.77 CDK7 (0.36) —
SCHEMBL11744578 0.75 MAPT (0.48) KDM4EHTTMAPTNPC1ALDH1A1
SCHEMBL15288145 0.74 CSNK2A1 (0.46) KDM4EHTTCSNK2A1ALDH1A1HPGD
SCHEMBL11743775 0.72 KMT2A (0.47) KDM4EHTTMAPTNPC1ALDH1A1
SCHEMBL20697183 0.72 KDM4E (0.56) KDM4EHTTMAPTNPC1ALDH1A1
SCHEMBL25117949 0.72 KDM4E (0.54) KDM4EMAPTNPC1ALDH1A1HPGD
SCHEMBL22413202 0.72 ALDH1A1 (0.34) KDM4EHTTMAPTALDH1A1
SCHEMBL21754310 0.71 STAT1 (0.36) KDM4EMAPTNPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
CN-110831600-B Indole AHR inhibitors and uses thereof 医肯纳肿瘤学公司 2023-10-17 — — CN disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
EP-3612030-A2 INDOLE AHR INHIBITORS AND USES THEREOF Kyn Therapeutics (US) 2020-02-26 — — EP disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
CN-110831600-A Indole AHR inhibitors and uses thereof 金恩医疗公司 2020-02-21 — — CN disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed
WO-2018195397-A2 INDOLE AHR INHIBITORS AND USES THEREOF KYN THERAPEUTICS (US) 2018-10-25 — — WO disclosed
US-20090247501-A1 PROTEIN KINASE INHIBITORS POLARIS GROUP (TW) 2009-10-01 — — US disclosed
US-7517882-B2 Protein kinase inhibitors POLARIS GROUP (CN) 2009-04-14 — — US disclosed
US-20080070893-A1 Protein Kinase Inhibitors POLARIS GROUP (CN) 2008-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KDM4E 923/4885HTT 274/4885CSNK2A1 2450/4885
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KDM4E 923/4885HTT 274/4885CSNK2A1 2450/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KDM4E 923/4885HTT 274/4885CSNK2A1 2450/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KDM4E 923/4885HTT 274/4885CSNK2A1 2450/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KDM4E 923/4885HTT 274/4885CSNK2A1 2450/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KDM4E 923/4885HTT 274/4885CSNK2A1 2450/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KDM4E 923/4885HTT 274/4885CSNK2A1 2450/4885
US-20080070893-A1 Protein Kinase Inhibitors MAP3K15, MAP3K20, MAP3K5 KDM4E 1864/4885HTT 2466/4885CSNK2A1 482/4885
US-20090247501-A1 PROTEIN KINASE INHIBITORS MAP3K15, MAP3K20, MAP3K5 KDM4E 1864/4885HTT 2466/4885CSNK2A1 482/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KDM4E 923/4885HTT 274/4885CSNK2A1 2450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.